{
    "organizations": [],
    "uuid": "7fd0809b64b9142042cda56e7e54f79d00238e92",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-lynparza-tablets-receive-eu-approv/brief-lynparza-tablets-receive-eu-approval-for-the-treatment-of-platinum-sensitive-relapsed-ovarian-cancer-idUSFWN1SF0KS",
    "ord_in_thread": 0,
    "title": "BRIEF-Lynparza (Olaparib) Tablets Receive EU Approval For The Treatment Of Platinum-Sensitive Relapsed Ovarian Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Merck & Co Inc:\n* LYNPARZAÂ® (OLAPARIB) TABLETS RECEIVE EU APPROVAL FOR THE TREATMENT OF PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER\n* MERCK & CO INC - NEW TABLET FORMULATION REDUCES DOSING TO TWO TABLETS TWICE DAILY\n* MERCK - EMA APPROVED LYNPARZA TABLETS (300 MG TWICE DAILY) FOR USE AS A MAINTENANCE THERAPY WITH PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-08T18:55:00.000+03:00",
    "crawled": "2018-05-09T12:17:37.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "merck",
        "co",
        "inc",
        "olaparib",
        "tablet",
        "receive",
        "eu",
        "approval",
        "treatment",
        "relapsed",
        "ovarian",
        "cancer",
        "merck",
        "co",
        "inc",
        "new",
        "tablet",
        "formulation",
        "reduces",
        "dosing",
        "two",
        "tablet",
        "twice",
        "daily",
        "merck",
        "ema",
        "approved",
        "lynparza",
        "tablet",
        "mg",
        "twice",
        "daily",
        "use",
        "maintenance",
        "therapy",
        "relapsed",
        "ovarian",
        "cancer",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}